Drugs / TOOKAD
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Tookad | — | 2017-11-10 | europa.eu ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00305929 | Mar 2006 → Dec 2007 | prostate cancer | STEBA France | Completed | No outcome recorded |
| Phase 2 | NCT00308919 | Apr 2004 → Nov 2005 | prostate carcinoma | STEBA France | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00312442 | May 2006 → Jul 2008 | prostate cancer | STEBA France | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04225299 | Mar 2020 → Mar 2030 | cancer | Steba Biotech S.A. | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03849365 | Jan 2019 → Nov 2020 | — | Steba Biotech S.A. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tookad | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00305929 ↗ |
| Known as | WST09 | “This is a multi-centre, phase II, open-label, 12-month clinical trial for patients previously treated with WST09 (Tookad) who have positive prostate biopsies for cancer.” NCT00305929 ↗ |
| Modality | Other / unclassified | “vascular-targeted photodynamic treatment (VTP) with WST09 (Tookad)” NCT00305929 ↗ |
| Route | Intravenous | “an I.V. infusion of WST09 (Tookad)” NCT00305929 ↗ |